Daniel Naranjo | Head of Patient Safety & Risk Management
Bicara Therapeutics

Daniel Naranjo, MD
Dr. Daniel Naranjo is a senior biotechnology and pharmaceutical safety leader with deep expertise in oncology and hematology drug development. A former combat veteran, research physician, and he is recognized for pioneering predictive risk modeling and advancing proactive safety strategies across the industry. He has successfully led global benefit–risk assessments, risk minimization, early and post-launch safety programs. In addtion Dr. Naranjo has led the removal of complex risk management requirements across major markets. Dr. Naranjo’s leadership has been recognized with multiple R&D awards for innovative approaches to predictive safety analysis and cardiovascular risk in oncology. His extensive experience spans submissions accross 6 drug indications to include safety initiatives while creating and builting organizational leadership excellence in patient safety science organizations.